Molecular basis of adrenocortical carcinomas.
Adrenocortical carcinomas (ACCs) are rare tumors associated with poor prognosis. Although surgery is the mainstay of treatment for this cancer, most patients will experience a recurrence of their tumor. Adjuvant therapies currently include mitotane, radiotherapy and chemotherapy, but responses to these therapies, however, are poor. A better understanding of the molecular basis of this cancer is crucial to the development of newer and better treatment options. This review summarizes the current knowledge of the molecular basis of ACCs.
Soon
P S H
PS
Department of Surgery, Bankstown Hospital and South West Clinical School, University of New South Wales, Sydney, Australia. patsysoon@med.usyd.edu.au
Sidhu
S B
SB
D000306:Adrenal Cortex Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D018268:Adrenocortical Carcinoma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D006801:Humans; D019656:Loss of Heterozygosity; D009154:Mutation; D009386:Neoplastic Syndromes, Hereditary / Q000235:genetics*; D011379:Prognosis; D016896:Treatment Outcome